263 related articles for article (PubMed ID: 19930682)
1. Nuclear detection of Y-box protein-1 (YB-1) closely associates with progesterone receptor negativity and is a strong adverse survival factor in human breast cancer.
Dahl E; En-Nia A; Wiesmann F; Krings R; Djudjaj S; Breuer E; Fuchs T; Wild PJ; Hartmann A; Dunn SE; Mertens PR
BMC Cancer; 2009 Nov; 9():410. PubMed ID: 19930682
[TBL] [Abstract][Full Text] [Related]
2. Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes.
Habibi G; Leung S; Law JH; Gelmon K; Masoudi H; Turbin D; Pollak M; Nielsen TO; Huntsman D; Dunn SE
Breast Cancer Res; 2008; 10(5):R86. PubMed ID: 18925950
[TBL] [Abstract][Full Text] [Related]
3. The value of cytoplasmic Y-box-binding protein 1 as a prognostic marker for breast cancer in Korean.
Lee A; Woo J; Park H; Sung SH; Seoh JY; Lim W; Moon BI
Breast Cancer; 2016 Sep; 23(5):685-91. PubMed ID: 26193840
[TBL] [Abstract][Full Text] [Related]
4. Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Darb-Esfahani S; Loibl S; Müller BM; Roller M; Denkert C; Komor M; Schlüns K; Blohmer JU; Budczies J; Gerber B; Noske A; du Bois A; Weichert W; Jackisch C; Dietel M; Richter K; Kaufmann M; von Minckwitz G
Breast Cancer Res; 2009; 11(5):R69. PubMed ID: 19758440
[TBL] [Abstract][Full Text] [Related]
5. Akt-dependent nuclear localization of Y-box-binding protein 1 in acquisition of malignant characteristics by human ovarian cancer cells.
Basaki Y; Hosoi F; Oda Y; Fotovati A; Maruyama Y; Oie S; Ono M; Izumi H; Kohno K; Sakai K; Shimoyama T; Nishio K; Kuwano M
Oncogene; 2007 Apr; 26(19):2736-46. PubMed ID: 17072343
[TBL] [Abstract][Full Text] [Related]
6. Nuclear Y-box-binding protein-1 is a poor prognostic marker and related to epidermal growth factor receptor in uterine cervical cancer.
Nishio S; Ushijima K; Yamaguchi T; Sasajima Y; Tsuda H; Kasamatsu T; Kage M; Ono M; Kuwano M; Kamura T
Gynecol Oncol; 2014 Mar; 132(3):703-8. PubMed ID: 24486603
[TBL] [Abstract][Full Text] [Related]
7. Expression of HER2 and estrogen receptor alpha depends upon nuclear localization of Y-box binding protein-1 in human breast cancers.
Fujii T; Kawahara A; Basaki Y; Hattori S; Nakashima K; Nakano K; Shirouzu K; Kohno K; Yanagawa T; Yamana H; Nishio K; Ono M; Kuwano M; Kage M
Cancer Res; 2008 Mar; 68(5):1504-12. PubMed ID: 18316615
[TBL] [Abstract][Full Text] [Related]
8. Expression of Y-Box-binding protein 1 in Chinese patients with breast cancer.
Xie W; Yang J; Cao Y; Peng C; Ning H; Zhang F; You J
Tumour Biol; 2012 Feb; 33(1):63-71. PubMed ID: 21968648
[TBL] [Abstract][Full Text] [Related]
9. Nuclear YB-1 expression as a negative prognostic marker in nonsmall cell lung cancer.
Gessner C; Woischwill C; Schumacher A; Liebers U; Kuhn H; Stiehl P; Jürchott K; Royer HD; Witt C; Wolff G
Eur Respir J; 2004 Jan; 23(1):14-9. PubMed ID: 14738225
[TBL] [Abstract][Full Text] [Related]
10. Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1.
Janz M; Harbeck N; Dettmar P; Berger U; Schmidt A; Jürchott K; Schmitt M; Royer HD
Int J Cancer; 2002 Jan; 97(3):278-82. PubMed ID: 11774277
[TBL] [Abstract][Full Text] [Related]
11. Nuclear Y-box binding protein-1, a predictive marker of prognosis, is correlated with expression of HER2/ErbB2 and HER3/ErbB3 in non-small cell lung cancer.
Kashihara M; Azuma K; Kawahara A; Basaki Y; Hattori S; Yanagawa T; Terazaki Y; Takamori S; Shirouzu K; Aizawa H; Nakano K; Kage M; Kuwano M; Ono M
J Thorac Oncol; 2009 Sep; 4(9):1066-74. PubMed ID: 19648825
[TBL] [Abstract][Full Text] [Related]
12. Y-box binding protein, YB-1, as a marker of tumor aggressiveness and response to adjuvant chemotherapy in breast cancer.
Huang J; Tan PH; Li KB; Matsumoto K; Tsujimoto M; Bay BH
Int J Oncol; 2005 Mar; 26(3):607-13. PubMed ID: 15703814
[TBL] [Abstract][Full Text] [Related]
13. Prognostic association of YB-1 expression in breast cancers: a matter of antibody.
Woolley AG; Algie M; Samuel W; Harfoot R; Wiles A; Hung NA; Tan PH; Hains P; Valova VA; Huschtscha L; Royds JA; Perez D; Yoon HS; Cohen SB; Robinson PJ; Bay BH; Lasham A; Braithwaite AW
PLoS One; 2011; 6(6):e20603. PubMed ID: 21695211
[TBL] [Abstract][Full Text] [Related]
14. Nuclear Y-Box-binding Protein-1 Expression Predicts Poor Clinical Outcome in Stage III Colorectal Cancer.
Shiraiwa S; Kinugasa T; Kawahara A; Mizobe T; Ohchi T; Yuge K; Fujino S; Katagiri M; Shimomura S; Tajiri K; Sudo T; Kage M; Kuwano M; Akagi Y
Anticancer Res; 2016 Jul; 36(7):3781-8. PubMed ID: 27354655
[TBL] [Abstract][Full Text] [Related]
15. Systematic antibody generation and validation via tissue microarray technology leading to identification of a novel protein prognostic panel in breast cancer.
O Leary PC; Penny SA; Dolan RT; Kelly CM; Madden SF; Rexhepaj E; Brennan DJ; McCann AH; Pontén F; Uhlén M; Zagozdzon R; Duffy MJ; Kell MR; Jirström K; Gallagher WM
BMC Cancer; 2013 Apr; 13():175. PubMed ID: 23547718
[TBL] [Abstract][Full Text] [Related]
16. Neuronal protein synuclein gamma predicts poor clinical outcome in breast cancer.
Guo J; Shou C; Meng L; Jiang B; Dong B; Yao L; Xie Y; Zhang J; Chen Y; Budman DR; Shi YE
Int J Cancer; 2007 Sep; 121(6):1296-305. PubMed ID: 17534899
[TBL] [Abstract][Full Text] [Related]
17. Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer.
Jögi A; Brennan DJ; Rydén L; Magnusson K; Fernö M; Stål O; Borgquist S; Uhlen M; Landberg G; Påhlman S; Pontén F; Jirström K
Mod Pathol; 2009 Dec; 22(12):1564-74. PubMed ID: 19734850
[TBL] [Abstract][Full Text] [Related]
18. IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype.
Walter O; Prasad M; Lu S; Quinlan RM; Edmiston KL; Khan A
Hum Pathol; 2009 Nov; 40(11):1528-33. PubMed ID: 19695680
[TBL] [Abstract][Full Text] [Related]
19. YB-1, the E2F pathway, and regulation of tumor cell growth.
Lasham A; Samuel W; Cao H; Patel R; Mehta R; Stern JL; Reid G; Woolley AG; Miller LD; Black MA; Shelling AN; Print CG; Braithwaite AW
J Natl Cancer Inst; 2012 Jan; 104(2):133-46. PubMed ID: 22205655
[TBL] [Abstract][Full Text] [Related]
20. [Studies of YB-1 protein in breast tumors].
Gens GP; Stromskaia TP; Kalita OV; Vaĭman AV; Rybalkina EIu; Ovchinnikov LP; Sorokin AV; Korobkova LI; Astrakhantsev AF; Mukha SF; Moiseeva NI; Stavrovskaia AA
Klin Lab Diagn; 2009 Apr; (4):21-4. PubMed ID: 19517610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
